A share price of Regeneron Pharmaceuticals, Inc [REGN] is currently trading at $716.72, up 2.82%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The REGN shares have gain 4.29% over the last week, with a monthly amount drifted -0.20%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] stock has seen the most recent analyst activity on February 05, 2025, when Leerink Partners upgraded its rating to a Outperform and also boosted its price target to $834 from $762. Previously, UBS downgraded its rating to Neutral on January 16, 2025, and dropped its price target to $738. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $1150 on November 15, 2024. Citigroup initiated its recommendation with a Neutral and recommended $895 as its price target on November 14, 2024. Leerink Partners downgraded its rating to Market Perform for this stock on September 24, 2024, and downed its price target to $1077. In a note dated March 12, 2024, Bernstein initiated an Outperform rating and provided a target price of $1125 on this stock.
Regeneron Pharmaceuticals, Inc experienced fluctuations in its stock price throughout the past year between $642.00 and $1211.20. Currently, Wall Street analysts expect the stock to reach $1144.1 within the next 12 months. Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] shares were valued at $716.72 at the most recent close of the market. An investor can expect a potential return of 59.63% based on the average REGN price forecast.
Analyzing the REGN fundamentals
Trailing Twelve Months sales for Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] were 14.20B which represents 10.33% growth. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at 0.28%, Pretax Profit Margin comes in at 0.34%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.15 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 701.40 points at the first support level, and at 686.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 730.64, and for the 2nd resistance point, it is at 744.57.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] is 5.57. As well, the Quick Ratio is 4.94. Considering the valuation of this stock, the price to sales ratio is 5.55, the price to book ratio is 2.69 and price to earnings (TTM) ratio is 18.72.
Transactions by insiders
Recent insider trading involved McCourt Marion, EVP Commercial, that happened on Nov 01 ’24 when 1000.0 shares were sold. Officer, MARION E MCCOURT completed a deal on Nov 01 ’24 to buy 1000.0 shares. Meanwhile, Director RYAN ARTHUR F sold 100.0 shares on Oct 01 ’24.
